Carvalho J A, Nunes P, Dinis P J, Antunes H, Parada B, Marconi L, Moreira P, Roseiro A, Bastos C, Rolo F, Dias V, Figueiredo A
Urology and Renal Transplantation Department, Coimbra University Hospital Center, Coimbra, Portugal.
Urology and Renal Transplantation Department, Coimbra University Hospital Center, Coimbra, Portugal.
Transplant Proc. 2017 May;49(4):809-812. doi: 10.1016/j.transproceed.2017.03.006.
We currently know that prostate cancer (Pca) risk is reduced in patients undergoing kidney transplantation. However, its impact and treatment are not widely studied.
This was a retrospective study of male patients submitted to kidney transplantation in our center from 1980 to 2016 evaluating incidence, treatment, and follow-up of Pca in our population.
In 1805 patients undergoing kidney transplantation, 20 men were diagnosed with Pca, leading to an incidence of 1.1%. Median age at renal transplantation was 53.4 years with a median age at diagnosis of Pca of 61.2 years. Initial median prostate-specific antigen (PSA) was 6 ng/mL and Gleason score was 7 (3 + 4) in about 50% of cases. Bone metastasis developed in 10% and no visceral metastases were diagnosed. The majority of patients were submitted to radical prostatectomy and bilateral pelvic lymph node dissection. Some other cancers occurred in these patients such as skin and pulmonary cancers. In 35% of the cases, the graft was lost. The main cause of patient death was cardiovascular. The mean graft survival was about 14 years. The majority of patients are alive with functioning grafts (65%).
In our center the clinical incidence of Pca in patients undergoing kidney transplantation is 1.1% and surgical treatment seems to be a good initial option.
我们目前知道，接受肾移植的患者前列腺癌（Pca）风险降低。然而，其影响和治疗尚未得到广泛研究。
这是一项对1980年至2016年在我们中心接受肾移植的男性患者的回顾性研究，评估我们人群中Pca的发病率、治疗和随访情况。
在1805例接受肾移植的患者中，20例男性被诊断为Pca，发病率为1.1%。肾移植时的中位年龄为53.4岁，Pca诊断时的中位年龄为61.2岁。初始中位前列腺特异性抗原（PSA）为6 ng/mL，约5０%的病例Gleason评分为7（3 + 4）。10%发生骨转移，未诊断出内脏转移。大多数患者接受了前列腺根治术和双侧盆腔淋巴结清扫术。这些患者还发生了其他一些癌症，如皮肤癌和肺癌。35%的病例移植失败。患者死亡的主要原因是心血管疾病。移植的平均存活时间约为14年。大多数患者存活且移植肾功能良好（65%）。
在我们中心，接受肾移植患者中Pca的临床发病率为1.1%，手术治疗似乎是一个不错的初始选择。
